Buy Current Challenges in Cell Therapy for Neurodegenerative Diseases
close menu
Bookswagon
search
My Account
Home > Medical specialties, branches of medicine > Neurology and clinical neurophysiology > Current Challenges in Cell Therapy for Neurodegenerative Diseases: Volume 166(Volume 166 International Review of Neurobiology)
Current Challenges in Cell Therapy for Neurodegenerative Diseases: Volume 166(Volume 166 International Review of Neurobiology)

Current Challenges in Cell Therapy for Neurodegenerative Diseases: Volume 166(Volume 166 International Review of Neurobiology)


     0     
5
4
3
2
1



Available


X
About the Book

International Review of Neurobiology

Table of Contents:
1. Challenges in translating a cell therapy to GMP  Gerhard Bauer 2. The challenges in developing a cell therapy for Huntington’s disease. Anne Rosser 3. Challenges of cell therapies for retinal diseases Christell Monville 4. Challenges of gene therapy in Huntington’s Disease 5. Technological advances and barriers to gene therapy 6. Considerations in the development of cell therapy modulation for spinal cord injury treatment Michael Aron Lane 7. Challenges of developing glial cell therapy for ALS Michal Izrael 8. Exploring cell and gene therapy in current animal models of Parkinson’s and Huntington’s disease Mariah J. Lelos 9. Considerations for the use of biomaterials to support cell therapy in degenerative disease James Benjamin Phillips 10. Neurosurgical challenges/innovations in cell and gene therapy delivery William Gray 11. Neuroimaging: the challenge of harnessing imaging tools to facilitate cell and gene therapy in neurodegenerative diseases/The contribution and challenges for imaging in advanced therapies of movement disorders 12. Considerations for clinical trial design for novel advanced therapeutics in neurodegenerative disease Cheney Drew and Monica Busse 13. More than a trial participant: The role of the patient in ATMP development and trials for neurodegenerative disease Emma Lane

About the Author :
I was promoted to Reader in Neuropharmacology in 2020 having been a Senior Lecturer since 2015. I was Director of Postgraduate Research Studies for 5 years, managing all the PhD students in the school, in particular supporting them as they navigated a PhD during the COVID pandemic. I established my own group in 2009 as a Lecturer in Pharmacology at the School of Pharmacy and Pharmaceutical Sciences. This group has focused on Parkinson's disease and now has a profile of research in both lab and patient-facing activities. I first came to Wales in 2006 as a PDRA working with Prof Stephen Dunnett (2006-2009) in the Brain Repair Centre, Department of Neuroscience, Cardiff University. Here I continued my work on L-dopa and post-transplantation dyskinesia started in Lund, Sweden, contributing to two successful EU FP7 grant awards. Following my PhD (2004-2006) I was a Post-Doctoral Research Associate in the Units of Neuronal Survival and Basal Ganglia Pathophysiology, Lund University, Sweden. I spent 2 years in Sweden with Prof Patrik Brundin and Prof Angela Cenci developing, characterizing and working with a model of post-transplantation dyskinesia. My PhD was conducted at King's College London, UK (2000-2004). I had a BBSRC CASE award studentship with Prof Peter Jenner and Dr Sharon Cheetham (then Knoll Pharmaceuticals) on the potential of BTS 74398, a monoamine uptake inhibitor, as a possible anti-parkinsonian medication in rodent models of the disease. My undergraduate degree was a BSc in Pharmacology (1996-2000) achieving a 1st class Honours with industrial placement, University College London, UK. Specialising in neuropharmacology options and spending an industrial year at Knoll Pharmaceuticals working on the pharmacology of the anti-obesity agent sibutramine. I am a research fellow and senior trials manager for the Mind, Brain Neuroscience study portfolio at the Centre for Trials Research in Cardiff University. I have a background in pharmacological research, with particular reference to neurodegenerative diseases, having completed my PhD in Huntington’s disease. Since transitioning to clinical research, I have been involved in the development and delivery of trials aimed at evaluating interventions (non-pharmacological and novel advanced therapies) in people with Huntington’s disease and other neurological disorders including Tuberous Sclerosis and epilepsy. I am member of the European Huntington’s Disease Network advanced therapies working group, aimed at devising the most efficient and robust methods for evaluating novel, non-traditional, treatments for this rare disorder. Given the complex and experimental nature of advanced therapies, I am particularly interested in how participants are approached, informed and provide consent to involvement in these trials. This includes listening to the participant voice as a central tenet of trial design. My PhD (2005-2010, Prof M Good) investigated neural network dysfunction using mathematical modelling in a mouse model of Alzheimer's disease, with a particular focus on amyloid-induced dysfunction in the amydala and hippocampal formation. My post-doctoral research (2010-2015, Prof S Dunnett) aimed to understand basal ganglia dysfunction in Parkinson's and Huntington's disease and to explore the use of human fetal and novel stem cell derived therapies to alleviate the behavioural impairments. I was awarded a Senior Research Fellowship from Parkinson's UK (2015-2018) to investigate the ability of human stem cell derived cell therapy products to ameliorate cognitive impairments in rodent models of Parkinson's disease. I have recently commenced a Senior Lectureship in the neuroscience department and my lab is exploring several new avenues. We are seeking to establish novel cell therapies to treat Parkinson's and Huntington's diseases, using novel DREADDs manipulations, undertaking PET/MR imaging and using rabies tracing technologies. We are also studying the impact of novel gene therapies on cellular function and on cognitive dysfunction.


Best Sellers


Product Details
  • ISBN-13: 9780323989374
  • Publisher: Elsevier Science & Technology
  • Publisher Imprint: Academic Press Inc
  • Height: 229 mm
  • No of Pages: 324
  • Sub Title: Volume 166
  • Width: 152 mm
  • ISBN-10: 0323989373
  • Publisher Date: 16 Nov 2022
  • Binding: Hardback
  • Language: English
  • Series Title: Volume 166 International Review of Neurobiology
  • Weight: 657 gr


Similar Products

Add Photo
Add Photo

Customer Reviews

REVIEWS      0     
Click Here To Be The First to Review this Product
Current Challenges in Cell Therapy for Neurodegenerative Diseases: Volume 166(Volume 166 International Review of Neurobiology)
Elsevier Science & Technology -
Current Challenges in Cell Therapy for Neurodegenerative Diseases: Volume 166(Volume 166 International Review of Neurobiology)
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Current Challenges in Cell Therapy for Neurodegenerative Diseases: Volume 166(Volume 166 International Review of Neurobiology)

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    Fresh on the Shelf


    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!
    Your IP: 216.73.216.196 IN